AccueilRARE • NASDAQ
add
Ultragenyx Pharmaceutical Inc
Dernière clôture
47,36 $
Variation sur la journée
47,04 $ - 47,82 $
Plage sur l'année
37,02 $ - 60,37 $
Capitalisation boursière
4,35 Md USD
Volume moyen
809,28 k
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Actualités
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | 139,49 M | 42,27 % |
Charges d'exploitation | 250,46 M | 7,88 % |
Résultat net | -133,52 M | 16,37 % |
Marge bénéficiaire nette | -95,71 | 41,22 % |
Bénéfice par action | -1,40 | 37,22 % |
EBITDA | -123,23 M | 10,64 % |
Taux d'imposition effectif | -0,23 % | — |
Bilan
Total des actifs
Total du passif
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 607,51 M | 37,42 % |
Total des actifs | 1,54 Md | 24,25 % |
Total du passif | 1,18 Md | -1,81 % |
Total des capitaux propres | 353,83 M | — |
Actions en circulation | 92,28 M | — |
Ratio cours/valeur comptable | 12,60 | — |
Rentabilité des actifs | -20,90 % | — |
Retour sur capitaux | -25,14 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Résultat net | -133,52 M | 16,37 % |
Trésorerie (opérations) | -67,00 M | 43,16 % |
Trésorerie (invest.) | -275,50 M | -528,50 % |
Trésorerie (financement) | 11,17 M | -55,72 % |
Variation nette en trésorerie | -330,05 M | -1 035,71 % |
Flux de trésorerie dispo. | -23,26 M | 65,84 % |
À propos
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
CEO
Date de fondation
2010
Siège social
Site Web
Employés
1 276
